The Food and Drug Administration (FDA) in the United States is calling for more data before approving MDMA for the treatment of post-traumatic stress disorder (PTSD).  – this is not a vote against MDMA, it is a call for more robust data. A critical distinction to make.

With no new PTSD drugs approved in over 20 years, this decision simply underscores the urgent need for thorough, follow-up research.

Emyria’s proven success in delivering medication-assisted therapies under Australia’s rigorous regulatory framework demonstrates our unique readiness. Today, the Company was highlighted in a full-page feature in the Australian Financial Review by Health Editor Michael Smith titled “Psychedelics as a serious investment? These billionaires think so”.

The story explores, in detail, the investment opportunity and clinical impact of key players who are pioneering novel treatments for mental health conditions – including commentary from Emyria CEO and MD, Dr Michael Winlo.

By operating in Australia, a jurisdiction where this therapy is legally allowed, Emyria already has a distinct global advantage, and now a profound opportunity, to positively impact patient lives and gather the robust data required to advance this field.

Click here to read the article.